This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechnology: Archive
CDTX Stock Soars 218% YTD on Positive Updates From Influenza Program
by Zacks Equity Research
Cidara Therapeutics' shares surge 218% this year after its flu candidate CD388 hits key mid-stage study goals and advances into pivotal testing.
CRMDPositive Net Change CDTXPositive Net Change KNSAPositive Net Change PHARNegative Net Change
biotechnology biotechs medical pharmaceuticals
MRK vs. BMY: Which Pharma Stock Is the Smarter Pick Now?
by Ekta Bagri
Merck and Bristol Myers face diverging growth paths, with Keytruda driving MRK's momentum and BMY navigating generic headwinds.
BMYPositive Net Change MRKPositive Net Change
biotechnology biotechs cancer medical pharmaceuticals
Will BDTX's EGFR Inhibitor Bring a Paradigm Shift in NSCLC Treatment?
by Ekta Bagri
Black Diamond's silevertinib aims to challenge Tagrisso, offering broad EGFR mutation coverage, as key trial results are expected in late 2025.
AZNPositive Net Change JNJPositive Net Change BDTXPositive Net Change
biotechnology biotechs medical pharmaceuticals
QURE Stock Skyrockets on Meeting Goals in Huntington's Disease Study
by Zacks Equity Research
uniQure N.V. shares surge nearly 248% after its gene therapy candidate, AMT-130, met key goals in a pivotal Huntington's disease study.
CRMDPositive Net Change QUREPositive Net Change KNSAPositive Net Change PHARNegative Net Change
biotechnology biotechs gene-therapy genomics medical pharmaceuticals
ACAD Stock Down 10% Following Phase III Hyperphagia Study Failure
by Zacks Equity Research
Acadia Pharmaceuticals stock tumbles 10% after its phase III hyperphagia study failure, but growth remains driven by Nuplazid, Daybue and a robust pipeline.
CRMDPositive Net Change ACADNegative Net Change SLNOPositive Net Change KNSAPositive Net Change
biotechnology biotechs medical pharmaceuticals
HRMY Stock Down as Fragile X Syndrome Study Fails to Meet Goal
by Zacks Equity Research
Harmony Biosciences' shares plunge after ZYN002 failed in Fragile X, but Wakix sales and new epilepsy assets keep its pipeline moving forward.
HALONegative Net Change ANIPNegative Net Change HRMYPositive Net Change
biotechnology biotechs medical pharmaceuticals
REPL Stock Plunges 54% in 3 Months After FDA Rejects Skin Cancer Drug
by Zacks Equity Research
Replimune stock dives 54% over three months after the FDA rejects its RP1/Opdivo melanoma drug filing, delaying its first potential product launch.
BMYPositive Net Change CRMDPositive Net Change REPLPositive Net Change KNSAPositive Net Change
biotechnology biotechs medical pharmaceuticals
Gilead Sciences Surges 26.5% YTD: Buy, Sell or Hold the Stock?
by Zacks Equity Research
Gilead surges 26.5% YTD in 2025 as HIV franchise gains momentum with Yeztugo approval, offsetting cell therapy pressures.
GSKPositive Net Change MRKPositive Net Change GILDPositive Net Change
biotechnology biotechs medical pharmaceuticals
BMY Reports Positive Data From a Late-Stage Multiple Myeloma Study
by Zacks Equity Research
Bristol Myers reports positive phase III results for iberdomide in multiple myeloma, advancing its CELMoD pipeline and portfolio expansion.
BMYPositive Net Change HALONegative Net Change ANIPNegative Net Change BNTXNo Net Change
biotechnology biotechs medical pharmaceuticals
Time to Buy Pfizer (PFE) or Metsera (MTSR) Stock?
by Shaun Pruitt
Making a major move in the obesity drug market, Pfizer (PFE) announced on Monday that it plans to acquire biotechnology firm Metsera (MTSR).
PFEPositive Net Change MTSRNegative Net Change NVONegative Net Change LLYPositive Net Change
biotechnology dividends earnings investing medical pharmaceuticals vaccines
CRMD vs. MIRM: Which Specialized Biotech Stock is the Better Pick?
by Ahan Chakraborty
CorMedix and Mirum Pharmaceuticals are advancing niche therapies with strong launches, rising sales and strategic acquisitions shaping their growth.
PFEPositive Net Change AMPHPositive Net Change CRMDPositive Net Change MIRMNegative Net Change
biotechnology biotechs medical pharmaceuticals
BDTX vs. Cullinan Therapeutic: Which EGFR Challenger Is the Better Buy?
by Ekta Bagri
BDTX and Cullinan advance next-gen EGFR inhibitors, but silevertinib's potential and valuation tilt momentum toward BDTX.
BDTXPositive Net Change CGEMNegative Net Change
biotechnology biotechs medical pharmaceuticals
5 Biotech Stocks Worth Adding to Your Portfolio Now
by Ekta Bagri
New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry despite the uncertain macroeconomic environment. A strong portfolio and solid pipeline progress position HALO, AKRO, KSNA, ANIP and TWST in this volatile sector
HALONegative Net Change ANIPNegative Net Change KNSAPositive Net Change TWSTPositive Net Change AKROPositive Net Change
biotechnology biotechs medical pharmaceuticals
New Strong Sell Stocks for September 23rd
by Zacks Equity Research
ATS, ASRT and DBVT have been added to the Zacks Rank #5 (Strong Sell) List on September 23, 2025.
DBVTPositive Net Change ASRTNegative Net Change ATSNegative Net Change
biotechnology
Company News for Sep 23, 2025
by Zacks Equity Research
Companies In The News Are: ORCL, TAP, AAPL, MTSR, PFE.
AAPLNegative Net Change PFEPositive Net Change ORCLNegative Net Change TAPPositive Net Change MTSRNegative Net Change
biotechnology consumer-staples pharmaceuticals tech-stocks
Implied Volatility Surging for Eton Pharmaceuticals Stock Options
by Zacks Equity Research
Investors need to pay close attention to ETON stock based on the movements in the options market lately.
ETONPositive Net Change
biotechnology biotechs medical
SNY & REGN's Dupixent Receives CHMP Backing for Urticaria in EU
by Zacks Equity Research
Sanofi/Regeneron's Dupixent wins CHMP backing for chronic spontaneous urticaria in the EU, paving the way for expanded treatment options.
REGNPositive Net Change SNYPositive Net Change CRMDPositive Net Change KNSAPositive Net Change
biotechnology biotechs medical pharmaceuticals
FDA Extends Review Period of Sanofi's Multiple Sclerosis Drug Filing
by Zacks Equity Research
The FDA extends SNY's tolebrutinib NDA review by three months, with decision now expected on Dec. 28, 2025.
SNYPositive Net Change CRMDPositive Net Change KNSAPositive Net Change PHARNegative Net Change
biotechnology biotechs medical pharmaceuticals
Can Novo Nordisk Hold Its Edge as the GLP-1 Battle With LLY Heats Up?
by Zacks Equity Research
NVO gains ground in the GLP-1 battle as Ozempic outshines Trulicity in heart risk reduction and Rybelsus wins EU approval for added benefits.
NVONegative Net Change LLYPositive Net Change VKTXPositive Net Change
biotechnology biotechs medical pharmaceuticals
Can Bristol Myers Squibb's Restructuring Program Boost Earnings Growth?
by Ekta Bagri
Bristol Myers ramps up a $2.5B restructuring plan to cut costs, streamline operations, and offset pressure from generic competition.
BMYPositive Net Change NVONegative Net Change MRKPositive Net Change
biotechnology biotechs medical pharmaceuticals
Jefferies (JEF) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
JEFPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Should You Buy Shattuck Labs, Inc. (STTK) After Golden Cross?
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
STTKNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
INCY Obtains FDA Approval for Label Expansion of Ruxolitinib Cream
by Zacks Equity Research
Incyte secures FDA nod for Opzeluras pediatric use in atopic dermatitis, marking its third U.S. approval and boosting sales momentum.
NVSPositive Net Change QGENNegative Net Change INCYPositive Net Change
biotechnology biotechs medical pharmaceuticals
RHHBY to Acquire 89bio for $3.5B, Add Late-Stage MASH Drug to Pipeline
by Zacks Equity Research
Roche is set to acquire 89bio for $3.5B, adding late-stage MASH drug pegozafermin to its cardiovascular, renal, and metabolic pipeline.
GSKPositive Net Change NVSPositive Net Change RHHBYNegative Net Change ETNBNo Net Change
biotechnology biotechs medical pharmaceuticals
3 Promising Genomics & Synthetic Biology Stocks in Spotlight in 2025
by Ekta Bagri
GeneDx, Twist Bioscience and Wave Life Sciences are emerging as key players in the fast-growing genomics and synthetic biology space.
ILMNNegative Net Change BEAMNegative Net Change WVEPositive Net Change CRSPPositive Net Change TWSTPositive Net Change WGSPositive Net Change
biotechnology biotechs gene-editing genetics genomics medical pharmaceuticals